Mix vaccines, third dose, thrombosis cases: what Ema says

The first data and news on the mix of anti-Covid vaccines are reassuring, the third dose does not seem necessary and the lethality rate for rare thrombosis cases found after the administration of AstraZeneca and Johnson & Johnson has decreased. This is what the European Medicines Agency Ema reports. MIX VACCINES The possibility of mixing different vaccines between first and second dose “is a very important issue that is under discussion now. There are some data regarding this possibility, in particular with AstraZeneca and an mRna vaccine” for the second dose. “One study has been conducted in the UK and another should give results from Spain. But there are no particular concerns from a safety point of view and even the few data we have seen show that even in terms of immunogenicity it seems an effective approach to generate a robust immune response after a second dose of different vaccine. However, we are trying to gather more evidence and review studies to make sure this approach is as good as it sounds. ” This was explained by Marco Cavaleri, head of Vaccines and Therapeutic Products for Covid-19 of the European Medicines Agency EMA, during the periodic briefing held by the EU regulatory body. THIRD DOSE “Preliminary data on the duration of immunity, which could reach a year or even more, do not currently show the need for a third dose, but further evidence is needed”, tweeted the Ema, adding to be “in contact with the main producers of anti-Covid vaccines to address the issue of variants” of the coronavirus and “evaluate the best strategy for a possible third dose”. THROMBOSIS CASES Regarding “the risk of rare thrombosis” associated with low platelet levels was reported after the anti-Covid vaccination with AstraZeneca and Janssen (J&J), if for J&J we have only one possible case reported in Europe, for AstraZeneca ” , with whom a much higher number of people have been vaccinated at the moment in this area of ​​the world, “were added further reports. But what’s important to note is that the frequency of these rare adverse events hasn’t changed. It is approximately 1 “reported” case in 100 thousand. And another important observation is that the lethality rate has dropped, which probably indicates that the awareness of vaccinated people and the ability of doctors to treat “these cases” may have helped to reduce these unfortunate outcomes, “explained Georgy Genov. , Head of Pharmacoviliness of the European Medicines Agency Ema, today during the periodic briefing held by the EU regulatory body.